News | July 22, 2025
AstraZeneca plans to invest $50 billion in US by 2030
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Further strengthens BaseLaunch's global pharma industry partnerships
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
Subscribe To Our Newsletter & Stay Updated
